Advertisement
Advertisement
U.S. markets close in 5 hours 45 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Reneo Pharmaceuticals, Inc. (RPHM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.68000.0000 (0.00%)
As of 09:30AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close2.6800
Open2.6800
Bid2.5000 x 3000
Ask2.7700 x 800
Day's Range2.6800 - 2.6800
52 Week Range1.7900 - 6.4590
Volume219
Avg. Volume25,004
Market Cap65.739M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RPHM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Reneo Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

    IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30, 2022. “We continued to advance our REN001 development programs during the third quarter,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. “As of today, we have

  • GlobeNewswire

    Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

    IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at three upcoming healthcare conferences. Jefferies Global Healthcare Conference Date: November 15 – 17, 2022Location: The Waldorf Hilton, London, UK Piper Sandler Healthcare Conf

  • GlobeNewswire

    Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

    IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, announced two poster presentations at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual meeting, being held in Freiburg, Germany August 28-29, 2022. The poster presentations highlight the results of two rece

Advertisement
Advertisement